Penumbra revenue +14.9% to $390.0M, but net income falls 23% on tax spike; Boston Scientific deal pending

Filed July 30, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 29, 2025 · ~1 min read

Key Changes

• high

  Revenue rose 14.9% to $390.0M, but net income fell 23.1% to $34.8M as the effective tax rate jumped from 0.1% to 24.6%.

  MD&A: Results verify on EDGAR →
• high

  termination fees up to $525M (Penumbra) or $900M (Boston Scientific).

  Notes: Merger view on EDGAR →
• medium

  Cash and equivalents fell to $205.3M while marketable investments surged to $453.5M, reflecting a shift into higher-yielding short-term instruments.

  MD&A: Liquidity verify on EDGAR →